Redeye returns following IRLAB's Q3 report and recent news in the company. We largely reiterate our stance and conclude that the company has several important catalysts ahead - including a Pirepemat phase IIb readout.
ANNONS
Redeye returns following IRLAB's Q3 report and recent news in the company. We largely reiterate our stance and conclude that the company has several important catalysts ahead - including a Pirepemat phase IIb readout.